Cargando…

Optimal Glycemic Control in a Patient With HNF1A MODY With GLP-1 RA Monotherapy: Implications for Future Therapy

We present the case of a 27-year-old woman with inadequately controlled HNF1A maturity-onset diabetes of the young (MODY) who was successfully transitioned from sulfonylurea therapy to once-weekly monotherapy with dulaglutide, a glucagon-like peptide-1 receptor agonist (GLP-1 RA). More than a decade...

Descripción completa

Detalles Bibliográficos
Autores principales: Fantasia, Kathryn L, Steenkamp, Devin W
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Endocrine Society 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6846329/
https://www.ncbi.nlm.nih.gov/pubmed/31737858
http://dx.doi.org/10.1210/js.2019-00278

Ejemplares similares